Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis
about
Comparison of echinocandin antifungalsEndophthalmitis: Pathogenesis, clinical presentation, management, and perspectivesEvaluating retinal toxicity of intravitreal caspofungin in the mouse eye.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Pharmacokinetics and safety of intravitreal caspofungin.Penetration of topically administered 0.5-percent caspofungin eye drops into human aqueous humorAntifungal pharmacokinetics and pharmacodynamicsTreatment principles for Candida and Cryptococcus.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureIntermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infection.The pharmacology and clinical use of caspofungin.Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.Candida endophthalmitis: focus on current and future antifungal treatment options.Intraocular penetration of intravenous micafungin in inflamed human eyes.The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.Tissue penetration of antifungal agents.Antifungals to treat Candida albicans.Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy.Fungal endophthalmitis.Current pharmacological concepts for wise use of echinocandins in the treatment of Candida infections in septic critically ill patients.The Eagle-like effect of echinocandins: what's in a name?Our 2014 approach to breakthrough invasive fungal infections.Treatment principles for the management of mold infections.Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis.Risk of Fungal Endophthalmitis Associated with Cataract Surgery: A Mini-Review.Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes.Fungal echinocandin resistance.Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazolePharmacology of Systemic Antifungal AgentsTreatment of Invasive Candidiasis: A Narrative Review
P2860
Q28273738-A85C6A96-1A9A-4773-9F40-F136C96865E0Q33774225-58874AB8-EF83-4996-837E-7FA780CA8425Q34101326-AF232878-9976-4013-9246-9074A7D92935Q34505582-597BE293-2163-40B7-8BE7-3DFBE40B48FFQ34597632-E13B633F-093C-4357-B9C1-E1B76E60A606Q34737498-86B33B4B-ED33-4E0A-BAD0-C2B741D41576Q35663841-53EE8BC4-2388-4071-A390-ECE73E04C48EQ35664186-410A219B-5523-49D7-94E8-35EC49358A5DQ35959484-78ACEFD1-F601-4E0B-84A5-01A733296D04Q36276191-E1D32321-BD41-4A6C-87F9-D76E6A21EDA3Q36505301-BADC8579-43F3-4D06-986E-2BADB07E7C8CQ36788428-C08D7F23-5935-406E-9EAE-6AE7804617A6Q36822025-443D5240-3496-49BD-8355-1DEA8D772887Q37015976-A00F8D42-8629-4F2E-AD8B-AC3FF827C6C9Q37036540-BF191314-5988-4FF3-8B6F-BF2530B9BA2CQ37320912-E0574194-3785-43CB-99FE-98170290C283Q37544911-3A3978D5-C036-47C3-995C-8CFEBEE0FC28Q37763928-547A5F3E-E701-4EC1-9E9D-4EB9A13C3403Q37829260-649189C2-DA91-4AE1-A300-AEAA8F97C142Q37889382-A68E3F05-A659-45B2-B4AF-31F111021191Q37960568-D6CF1C2E-3484-4EB2-8D5F-33303DF43342Q38149163-DFD22429-7A75-41B2-8C38-531E7E36363AQ38153458-80C96829-1D37-481A-9E8D-1C31577C22E5Q38223105-4798A39D-6827-43CF-A7C0-D1132DB223ACQ38265845-58A25374-00C3-42C2-B447-CCA898503717Q38531765-5D05AAE8-AB3A-4AEE-B2AD-F649A7F8A1EDQ38576045-94ECF18D-9A30-4440-B49E-01B14F165ABCQ38586680-66B5E8A0-55B6-4E99-B9A1-7FC750800A46Q41848811-B886BB18-B485-42A7-8CC4-EDB79B696815Q56999041-D052E11E-D25E-468A-AD32-F898457E193AQ57533011-7ADC8281-89B0-405A-B294-1D835FD10288Q58772447-39BE13F2-9AC2-40E8-AEE8-B6849CE1E3CA
P2860
Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@ast
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@en
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@nl
type
label
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@ast
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@en
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@nl
prefLabel
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@ast
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@en
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@nl
P2093
P356
P1476
Subtherapeutic ocular penetrat ...... ndida albicans endophthalmitis
@en
P2093
P356
10.1086/431761
P407
P577
2005-08-01T00:00:00Z